Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma.

Journal Article (Journal Article)

DISCLOSURES: Koff: Burroughs Wellcome Fund: Research Funding; V Foundation: Research Funding; Lymphoma Research Foundation: Research Funding; American Association for Cancer Research: Research Funding. Leppä:Roche: Honoraria, Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen-Cilag: Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees. Gang:ROCHE: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Hsi:Abbvie: Research Funding; Eli Lilly: Research Funding; Cleveland Clinic&Abbvie Biotherapeutics Inc: Patents & Royalties: US8,603,477 B2; Jazz: Consultancy. Flowers:AbbVie: Consultancy, Research Funding; Denovo Biopharma: Consultancy; BeiGene: Consultancy, Research Funding; Burroughs Wellcome Fund: Research Funding; Eastern Cooperative Oncology Group: Research Funding; National Cancer Institute: Research Funding; V Foundation: Research Funding; Optimum Rx: Consultancy; Millenium/Takeda: Research Funding; TG Therapeutics: Research Funding; Gilead: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Karyopharm: Consultancy; AstraZeneca: Consultancy; Pharmacyclics/Janssen: Consultancy, Research Funding; Spectrum: Consultancy; Bayer: Consultancy; Acerta: Research Funding; Genentech, Inc./F. Hoffmann-La Roche Ltd: Consultancy, Research Funding. Neff:Enzyvant: Consultancy; EUSA Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees. Fedoriw:Alexion Pharmaceuticals: Other: Consultant and Speaker. Reddy:Genentech: Research Funding; BMS: Consultancy, Research Funding; Celgene: Consultancy; KITE Pharma: Consultancy; Abbvie: Consultancy. Mason:Sysmex: Honoraria. Behdad:Loxo-Bayer: Membership on an entity's Board of Directors or advisory committees; Thermo Fisher: Membership on an entity's Board of Directors or advisory committees; Pfizer: Other: Speaker. Burton:Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel; Celgene: Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. Dave:Data Driven Bioscience: Equity Ownership.

Full Text

Duke Authors

Cited Authors

  • Li, X; Kositsky, R; Reddy, A; Love, C; Naresh, K; Koff, JL; Nystrand, I; Leppä, S; Pasanen, A; Karjalainen-Lindsberg, M-L; Dunkel, J; Kovanen, P; Qin, Q; Bhagat, G; Leeman-Neill, RJ; Goswami, RS; Wildeman, S; Delabie, J; Burack, R; Evans, AG; Amador, C; Yuan, J; Qureishi, HN; Li, S; Xu, J; Yin, CC; Gang, AO; Norgaard, PH; Pedersen, MØ; Chan, JY; Cheah, DMZ; Ong, SY; Cheng, CL; Lee, L; Paulua, F; Ondrejka, SL; Hsi, ED; Czader, M; Wang, L; Landis, A; Churnetski, MC; Jaye, DL; Flowers, CR; McCall, CM; Neff, J; McKinney, MS; Fedoriw, Y; Powers, E; Montgomery, ND; Bogusz, AM; Stafford Hintz, A; Kovach, AE; Reddy, N; Thompson Arildsen, MA; Mason, EF; Juskevicius, R; Choi, W; Au-Yeung, R; Tse, E; Sarno, V; Chadburn, A; Lopez, R; Chapman, JR; Behdad, A; Goldschmidt, N; Goodlad, J; Burton, C; Pillai, R; Louissaint, A; Soliman, DS; Panea, R; Dave, T; Xiong, B; Smith, E; Dave, S

Published Date

  • November 13, 2019

Published In

Volume / Issue

  • 134 / Supplement_1

Start / End Page

  • 19 -

PubMed ID

  • 31723982

Pubmed Central ID

  • 31723982

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood-2019-130255

Language

  • eng

Conference Location

  • United States